Abstract The intracellular pharmacokinetics of the different classes of antimicrobials into surrogate markers of tissue accumulation (alveolar macrophages and/or total alveolar cells collected by means of bronchoalveolar lavage or peripheral white blood cells) was reviewed. The aim of this review was to discuss the clinical implications of the intracellular pharmacokinetics of antibacterials, either from the therapeutic or toxicological perspective. The different pharmacokinetic behaviour of antimicrobials within cells is mainly related to their physicochemical properties (hydrophilicity and lipophilicity), and may have several clinical implications. Therapeutic efficacy against intracellular pathogens has been correlated mainly with the intracellular concentrations achieved by the different antimicrobial agents. This is relevant especially for macrolides, tetracyclines, fluoroquinolones and rifampicin in the treatment of bacterial infections such as Legionella pneumophila pneumonia, Mycoplasma pneumoniae pneumonia, non-gonococcal urethritis and chronic staphylococcal infections. Additionally, intracellular accumulation of antibacterials was correlated with the possibility of causing organ-specific toxicity, as in the case of aminoglycosides in regard to the risk of nephrotoxicity. Finally, it should be kept in mind that intracellular accumulation may also represent a drug reservoir in the case of lipophilic antimicrobials. This may become extremely relevant from the clinical standpoint when treating critically ill patients with sepsis with antibacterials. The pathophysiology of sepsis may explain why it is necessary to start therapy with an increased loading dose of hydrophilic antimicrobials to promptly achieve therapeutically effective concentrations.
Introduction
The pharmacokinetic behaviour of drugs is conditioned mainly by their intrinsic physicochemical properties. In this regard, all drugs may be divided into two major groups according to the lipid-water partition coefficient, namely hydrophilic and lipophilic compounds. Indeed, it should be mentioned that categorisation of hydrophilic and lipophilic compounds is a dichotomisation of a continuous variable, and that the variation of lipid water partitioning should be acknowledged by clinicians within each group. This difference may affect the capability of drugs to pass through the plasmatic membrane of the eukaryotic cells. All of the lipophilic compounds may freely penetrate cells by means of passive diffusion according to the concentration gradient, even if drug transporters may reduce their intracellular concentrations. Conversely, the hydrophilic compounds may enter the cells only when in the presence of specific carriers [1] . As a general rule, the different pharmacokinetic behaviour of hydrophilic and lipophilic compounds may have major consequences from the clinical standpoint, either in terms of therapeutic efficacy or tolerability [2] .
With regard to drug efficacy, cellular penetration may represent a major issue when drugs should act intracellularly [2] . Conversely, this aspect is irrelevant when drugs are targeted at receptors located on the plasmatic membrane of the eukaryotic cell or outside of them. As far as drug toxicity is concerned, it is worth mentioning that drug sequestration within cells may cause accumulation in some organs with severe toxicity.
These aspects may become extremely relevant in the case of antibacterials. From a therapeutic perspective, most of the bacterial pathogens are typically located in the extracellular space. However, it should not be overlooked that some species behave as obligate intracellular pathogens (i.e. Legionella pneumophila) [3] . Others may behave as facultative pathogens (i.e. Staphylococcus aureus), and by embedding within cells may promote the chronicity of the infection process [3] . This aspect may clearly affect the efficacy of the various classes of antibacterials, which may be able to act against intracellular pathogens according to the amount of intracellular concentrations. From a toxicological perspective, intracellular sequestration may be responsible for accumulation into specific organs leading to severe toxicity, as for example in the case of nephrotoxicity for aminoglycosides [4] . The aim of this review is to discuss the clinical implications of the intracellular pharmacokinetics of antibacterials.
I performed a literature search in PubMed in the period between January 1978 and February 2017 using the following keywords: intracellular pharmacokinetics, alveolar macrophages, humans, antibacterials, aminoglycosides (amikacin, gentamicin, netilmicin, tobramycin) beta-lactams (ampicillin, amoxicillin, cefotaxime, ceftriaxone, ceftazidime, ertapenem, imipenem, meropenem, piperacillin) glycopeptides (teicoplanin, vancomycin), lipopeptides (daptomycin), fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin), glycylcyclines (tigecycline), fluorocycline (eravacycline), macrolides and ketolides (azithromycin, clarithromycin, telithromycin), oxazolidinones (linezolid, tedizolid), rifampicin, atypical pneumonia, chronic prostatitis, chronic staphylococcal infections, Chlamydia trachomatis, Legionella pneumophila, Mycoplasma genitalium, Mycoplasma pneumoniae and Ureaplasma urealiticum. The search process produced over 2000 articles, 103 of which were deemed relevant for clinical implications and included in the review. A detailed analysis of the intracellular pharmacodynamics of antibiotics is beyond the aim of this work, and for an exhaustive overview on this topic, the readers are referred to the reviews of Carryn et al. [5] and Van Bambeke et al. [3] .
Tissue Distribution and Intracellular
Pharmacokinetics of Antibacterials after Systemic Administration in Adults
The most informative pharmacokinetic parameter of drug intracellular penetration and sequestration within cells after systemic administration is the volume of distribution (V d ).
As a general rule, the V d is small for the hydrophilic compounds, as a consequence of a distribution that is limited to the extracellular milieu. Accordingly, for most hydrophilic compounds, V d does not exceed values that are the sum of the volume of plasma and of that of the interstitial fluids, namely 15-20 L for a typical 70-kg adult subject [1, 6] . This is because hydrophilic compounds may gain intracellular access only when carried through the plasmatic membrane of the eukaryotic cell. This may happen if they contain residues in their moieties, which may be recognised by specific carriers. Alternatively, in some cases, they might accumulate limitedly into phagocytes, as a consequence of endocytosis as a result of a host defence mechanism to kill bacteria [3] . Conversely, lipophilic compounds have free access to the intracellular compartment, thanks to passive diffusion through the plasmatic membrane [1] . This may explain why the V d of most lipophilic compounds may equate the volume of the total body fluids, or may even significantly exceed it whenever they are sequestered intracellularly. Figure 1 depicts the typical V d of the various antibacterials in normal healthy volunteers. Generally speaking, the larger the V d is, the higher the intracellular concentration should be, even if some exceptions to this rule may sometime exist. This property becomes clinically relevant when in the presence of infections caused by obligate or facultative intracellular pathogens. Only those antibacterials that may achieve high enough intracellular concentrations are usually indicated for the treatment of these infections.
Two different types of in vivo techniques are most frequently applied for measuring intracellular concentrations of antibiotics after systemic administration in humans. The first one is that of determining drug concentrations over time within the alveolar macrophages (AM) or the total alveolar cells (AC), which are collected by means of bronchoalveolar lavage. The second one is that of measuring concentrations within peripheral white blood cells (WBC), which are collected by means of blood sampling.
Measurement of drug concentrations within AM or AC over time is considered a valuable surrogate marker in predicting drug exposure during the treatment of pneumonia caused by intracellular pathogens [2] . This technique has been extensively applied, mainly for the macrolides and for the fluoroquinolones, but even for other classes of antibiotics, as summarised in Table 1 . Here, I discuss the most relevant clinical studies that assessed AM or AC concentrations after intravenous and/or oral administration of antimicrobials in adults.
Both of the so-called respiratory fluoroquinolones, namely levofloxacin and moxifloxacin, were studied in this regard. Rodvold et al. measured steady-state concentrations of levofloxacin in the plasma and AM of healthy adults after intravenous administration of 500 and/ or 750 mg once daily for five doses [7] . After both dosages, levofloxacin achieved much higher concentrations in AM than simultaneous concentrations in plasma, with maximum values (C max ) of [80 mg/L, and with AMto-plasma ratios persistently [10 in all of the analysed samples.
In another study, levofloxacin concentrations in AM were between 28.5 mg/L at 4 h and 8.2 mg/L at 24 h after oral administration of 500 mg every 24 h for five doses [8] . The AM-to-plasma ratios were [5 in all of the collected samples [8] . In the same study, the authors also assessed the intrapulmonary concentrations of moxifloxacin in another group of subjects. After oral administration of 400 mg of moxifloxacin once daily for five doses, the concentrations in AM peaked at 123.3 mg/L 8 h after the last administration, and the mean AM-to-plasma ratios over time were all [14 [8] .
Conte et al. assessed the concentration of levofloxacin in AC of healthy adult volunteers after a high dose of 1000 mg once daily for three doses [9] . Both the AC concentrations and the AC-to-plasma ratios achieved high values at all of the sampling times after the last dose (C max of 34.3 mg/L at 4 h, with AC-to-plasma ratios between 3.7 and 10). However, they did not increase in a proportional manner. This is in contrast with what was observed in other studies, in which lower doses of levofloxacin were used. This suggests that the intrapulmonary kinetics of high-dose levofloxacin could be non-linear.
Valuable levels in AM (peaking 38.5 mg/L at 4 h) with high penetration ratios between 2.3 and 4.8 were also observed among patients with acute exacerbations of chronic bronchitis who received levofloxacin 750 mg once daily orally for 5 days [10] . The penetration of ciprofloxacin in AM was assessed among non-infected patients undergoing diagnostic bronchoscopy [11] . After a single 500-mg oral dose, the AM concentrations peaked at 5 h (median of 7.6 mg/L), and the AM-to-plasma ratios were all [2. Azithromycin 500 mg q24 h IV for five doses [7] 649.9 669.4 734.0 1756.5 2677.6 5242.9
Azithromycin 500 mg LD day 1, 250 mg q24 h OS for four doses [8] 71 In two of the aforementioned studies concerning the respiratory fluoroquinolones [7, 8] , the authors assessed also the steady-state AM and plasma concentrations of azithromycin after intravenous (500 mg every 24 h for five doses) [7] and oral administration (500-mg loading dose followed by 250 mg every 24 h for four doses) [8] , respectively. The concentrations of azithromycin were always very high in AM ([70 mg/L and peaking at 734.0 mg/L at 24 h) and very low in plasma (always \0.5 mg/L), with large AM-to-plasma ratios (between 718.0 and 6841.3) [7, 8] .
Rodvold et al. assessed comparatively the intrapulmonary steady-state concentrations of azithromycin and clarithromycin in healthy adult volunteers [12] . The concentrations achieved by clarithromycin in AM after oral administration of 500 mg every 12 h for nine doses were always very high and declined progressively over time, with AM-to-plasma ratios always [100. Conversely, azithromycin, after oral administration of 500 mg on day 1 followed by four doses of 250 mg, 24 h apart, achieved high but more stable concentrations in AM over time with AM-to-plasma ratios persistently above 500. Similar findings for both clarithromycin and azithromycin were documented also by other authors [13] [14] [15] .
The concentrations of erythromycin in AC after oral administration of 250 mg every 6 h for nine doses were very low (\1 mg/L at 4, 8 and 12 h after the last dose). This led the authors to suggest that much higher dosages (up to 4 g daily) would have been necessary for the appropriate treatment of intracellular diseases [14] .
The intrapulmonary penetration of the ketolide antimicrobial telithromycin was assessed in two subsequent studies [16, 17] . After oral administration of 800 mg every 24 h for five doses, the median concentrations in AM peaked at 81.0 mg/L at 8 h in one study [16] , and 66.0 mg/ L at 12 h in the other study. [17] In both studies, the AMto-plasma ratios were [45.0 [16, 17] .
The pulmonary disposition of the new oxazolidinone tedizolid was assessed in healthy adult volunteers after oral administration of 200 mg every 24 h for three doses [18] . The concentrations in AM peaked at 4.4 mg/L at 6 h and the AM-to-plasma ratios were persistently C1.
The intrapulmonary penetration of linezolid in AM was assessed both among healthy volunteers [19] , and among non-infected patients undergoing diagnostic bronchoscopy [20] . The intracellular concentrations of linezolid after oral administration of 600 mg every 12 h for five doses to healthy volunteers were lower than those concomitantly observed in plasma (C max of 2.2 mg/L at 4 h), and the AMto-plasma ratios were always \0.2 [19] . The surprising findings led the authors to suppose that this could have been related to a rapid exclusion of the drug from the intracellular compartment [19] . In the other study, the mean concentration of linezolid in AM of patients after oral administration of 600 mg every 12 h for six doses was much higher (8.1 mg/L after a mean time of 5.1 h from the last administration), with a mean AM-to-plasma ratio closer to 0.7 [20] .
In a study with a similar design, the mean concentration of rifampicin in AM after the administration of a single oral dose of 600 mg was 251.8 mg/L after a mean time of 3.45 h, with a mean AM-to-plasma ratio of 16.3 [21] . The concentrations of tigecycline after administration of a loading dose of 100 mg on day 1 followed by 50 mg every 12 h for six doses to healthy volunteers were much higher in AC than in plasma in the period between 2 and 24 h after the last dose (peaking at 15.2 mg/L at 2 h). The AC-toplasma ratios were all [8 [22] .
The pulmonary disposition of the novel fluorocycline antibiotic eravacycline was assessed in a phase I open-label trial [23] . After intravenous administration of 1 mg/kg every 12 h for seven doses, eravacycline concentration in AM peaked at 8.25 mg/L at 2 h and levels in AM were persistently [30-fold higher than in plasma for 12 h [23] .
Measurement of drug concentrations into the peripheral WBC is the other technique used to measure intracellular concentrations of antibiotics after systemic administration in humans. This approach is considered a surrogate in determining whether an antibiotic may achieve therapeutically relevant concentrations against bacteria that may survive within the phagocytes after ingestion [24] . A notable example of this may be that of some strains of S. aureus, the so-called small colony variants (SCVs), which may cause chronicity of staphylococcal infections [25] . Table 2 summarises the C max achieved in WBC at steady state by the macrolides azithromycin and erythromycin, and by the fluoroquinolones moxifloxacin, levofloxacin and ciprofloxacin after oral administration of standard dosages. The C max was several-fold higher in WBC than in plasma for all of these antibacterials, with absolute values being more than tenfold higher than the clinical breakpoint for the intracellular pathogens. Azithromycin exhibited the highest WBC-to-plasma ratios with values always [80. This is owing to the peculiar dibasic molecular structure of this antibacterial agent, which is responsible for a unique ion-trapping sequestration within the acidic lysosomes of WBC [26] . As a consequence, intracellular concentrations of azithromycin may be elevated within WBC for several days, even after stopping administration, as recently documented by Matzneller et al. (WBC C max of 14.2 mg/L at day 10 after stopping azithromycin administration on day 3) [27] .
Overall, the analysis of these studies suggests that most lipophilic antibacterials may achieve therapeutically relevant intracellular concentrations within AM and/or WBC with valuable cellular-to-plasma ratios. The presence of documented intracellular-to-plasma ratios [0.5 provides a robust rationale for the therapeutic use of antibacterial classes against infections caused by intracellular pathogens, even if some notable exceptions may exist (Table 3) .
Clinical Implications
The intracellular accumulation of antimicrobial agents may have several clinical implications, either from a therapeutic or toxicological standpoint.
Therapeutic Implications
As far as antimicrobial efficacy is concerned, it is assumed that antimicrobial agents must achieve intracellular concentrations far above the intracellular minimum inhibitory concentration of the pathogens to be effective against intracellular infections. It may be supposed that the most effective antimicrobials should be those having high intracellular concentrations and accumulation. This has several confirmations from clinical practice, as supported by several clinical studies assessing the role of macrolides, ketolides, tetracyclines, fluoroquinolones and rifampicin in the treatment of infections caused by obligate and/or facultative intracellular pathogens.
Legionella pneumophila Pneumonia
One major example of intracellular infection is atypical pneumonia caused by L. pneumophila [28, 29] . L. pneumophila is an obligate intracellular pathogen, which typically resides in the AM [28] . Consistently, respiratory fluoroquinolones, macrolides, rifampicin, telithromycin and tetracyclines, according to their capability of concentrating within AM, are all antimicrobial agents considered effective in the treatment of Legionella pneumonia [2, 28, 29] .
The effectiveness of fluoroquinolones and of macrolides in the treatment of Legionella pneumonia was comparatively assessed in three early prospective open-label clinical studies [30] [31] [32] . One comparative study was carried out among 120 patients with documented Legionella pneumonia (positive antigenuria) who received an appropriate treatment with levofloxacin 500 mg every 24 h intravenously (n = 40) or with erythromycin 1000 mg every 6 h intravenously or with clarithromycin 500 mg every 12 h intravenously (n = 80). It was shown that patients who received levofloxacin had more rapid defervescence (2.0 vs. 4.5 days, p \ 0.001) and time to clinical stability (3 vs. 5 days, p = 0.002) [30] . This led the authors to conclude that levofloxacin, by ensuring faster clinical response than macrolides, may enable a shorter hospital stay.
Similarly, in another prospective observational study including 130 patients from three centres, fluoroquinolones (50 patients with levofloxacin and four with ofloxacin) were as effective as macrolides (33 patients with erythromycin and 43 patients with clarithromycin) in the treatment of Legionella pneumonia, and the time to [32] . In the third prospective study involving 292 patients with confirmed Legionella pneumonia, the comparative efficacy of levofloxacin (n = 143) and of macrolides (n = 65) was stratified according to the severity of illness (Fine score) [31] . No significant difference occurred between groups in term of clinical outcome for patients with mild or moderate disease. Conversely, levofloxacin resulted in a superior outcome compared with clarithromycin in those with severe pneumonia (fewer complications, 3.4 vs. 27.2% of patients, p = 0.02; shorter hospital stay, 5.5 vs. 11.3 days, p = 0.04). Additionally, in a subset of patients who were treated with the combination of levofloxacin plus rifampicin (n = 45), it was shown that rifampicin did not provide any additional benefits in comparison with patients who received levofloxacin alone [31] .
Similar findings were documented in a recent retrospective study carried out over a 15-year period (1995-2010), which included 214 patients with documented L. pneumophila pneumonia requiring hospitalisation at a university hospital [33] . Levofloxacin therapy was associated with a trend toward a shorter time to reach clinical stability (median, 3 vs. 5 days; p = 0.09) and a shorter length of hospital stay (median, 7 vs. 10 days; p \ 0.001) compared with macrolide use during hospital admission. Additionally, in the logistic regression analysis, macrolide use was found to be an independent factor associated with severe disease (intensive care unit admission and death) (odds ratio, 2.40; 95% confidence interval 1.03-5.56). Finally, it is worth noting that patients who received initial inappropriate therapy (with only beta-lactams) had more frequently an acute onset of illness (p = 0.004), pleuritic chest pain (p = 0.03) and pleural effusion (p = 0.05) in comparison with those who received appropriate empirical antibiotic therapy (with levofloxacin or with a macrolide with or without rifampicin). Similar findings were also documented in another small retrospective Japanese study [34] .
Overall, despite these studies having some critical flaws and limitations, they support the idea that whenever Legionella pneumonia is suspected, beta-lactam monotherapy should be avoided, and respiratory fluoroquinolones may exhibit a faster clinical response than macrolides. It might be speculated that the faster activity of fluoroquinolones could be related to the different pharmacodynamic behaviour of these classes of antibacterials. Despite both fluoroquinolones and macrolides achieving high concentrations in AM after systemic administration in humans, only fluoroquinolones exhibit potent and rapid concentration-dependent antibacterial activity against L. pneumophila in that environment [35] .
Other smaller clinical studies comparing fluoroquinolones with macrolides in the treatment of Legionella pneumonia showed only a trend in favour of levofloxacin in terms of time to clinical stability and of length of stay [36] or even no significant difference with similar response rates [37] .
Early clinical experiences also showed that the ketolide telithromycin may be effective in the treatment of Legionella pneumonia [38] , and there is also a case report on the treatment of a disseminated L. pneumophila infection (pneumonia and soft-tissue infection) in an immunocompromised patient successfully treated with tigecycline [39] .
Mycoplasma pneumoniae Pneumonia
Mycoplasma pneumoniae may represent a quite frequent cause of atypical pneumonia among children aged over 5 years [40] . It is known primarily as a mucosal pathogen lacking a rigid cell wall, which resides typically extracellularly. However, it has been demonstrated that it has the potential to fuse with and enter host cells that are not normally phagocytic [41] . It should be noted that this intracellular existence might impair the efficacy of some drug therapies, accounting for difficulty in eradicating the mycoplasmas under clinical conditions [41] .
Macrolides, tetracyclines and fluoroquinolones are considered the drugs of choice, but only macrolides are recommended in children [40, 42] . Currently, there is a worrisome emergence of macrolide-resistant M. pneumoniae [42] , which may pose relevant clinical challenges [43, 44] . It has been demonstrated that M. pneumoniae may develop macrolide resistance during macrolide treatment [43] . This could be owing to inappropriate microbiological eradication. Interestingly, an experimental animal study showed that escalating dosages of clarithromycin for the treatment of pneumonia caused by very susceptible strains of M. pneumoniae might significantly increase the antimicrobial efficacy (reduced quantitative cultures) and improve markers of disease severity (reduced lung histopathological score, cytokine levels and airway hyperresponsiveness) [45] . The authors concluded that this approach could theoretically represent an option for the clinical treatment of refractory infection [45] . Theoretically, it may also be hypothesised that this strategy, by improving microbiological eradication, might be helpful even in preventing the emergence of resistance. However, it should not be overlooked that safety data on high dosages of clarithromycin are currently lacking, and that clinical studies validating this hypothesis should be warranted.
The therapeutic efficacy of macrolides in the treatment of paediatric patients with confirmed macrolide-resistant M. pneumoniae pneumonia was recently compared with that of minocycline and tosufloxacin [46] . Interestingly, the average number of days of fever after the administration of antibiotic treatment was lower in the minocycline group (1.83 days, n = 38) than in the macrolide groups (3.06 days, n = 27 for azithromycin; 3.15 days, n = 23 for clarithromycin). Likewise, the bacteriological efficacy, estimated by the number of DNA copies of measured M. pneumoniae after 48-96 h of treatment, was more rapid in patients receiving minocycline (p = 0.016) than in those receiving azithromycin (p = 0.273) or clarithromycin (p = 0.107). Based on these findings, it was suggested that minocycline may be considered the first-choice drug for the treatment of M. pneumoniae pneumonia in children aged [8 years [46] . This choice should be considered especially in areas where the prevalence of macrolide-resistant M. pneumoniae is high. It has been suggested that in countries where macrolide-resistant M. pneumoniae strains are very common, the replacement of a macrolide by a tetracycline or a fluoroquinolone should be considered depending on the severity of the disease [42] .
Non-Gonococcal Urethritis and its Complications
Chlamydia trachomatis, Mycoplasma genitalium and Ureaplasma urealyticum are the most relevant aetiological agents of non-gonococcal urethritis, which is the most common treatable sexually transmitted syndrome in men [47] . These pathogens may also be found in the vaginal flora of pregnant women, and have been demonstrated to be involved in adverse perinatal outcomes. Both Mycoplasma and Ureaplasma may cause inflammation potentially leading to spontaneous preterm birth, as well as post-delivery infectious complications and neonatal infections [48] .
All of these pathogens behave as obligate or facultative intracellular pathogens [3, 49] . Macrolides, tetracyclines and fluoroquinolones are considered the drugs of choice for the treatment of these infections [47] . These classes of antibiotics showed similar cure rates in comparative studies performed in men with non-gonococcal urethritis [50] and with prostatitis [51] .
Several clinical studies comparatively assessed the efficacy of azithromycin and doxycycline in the treatment of Ureaplasma infections [52] [53] [54] , with no significant difference in clinical cure rates [53] . A recent meta-analysis of randomised controlled trials of azithromycin vs. doxycycline for the treatment of genital Chlamydia infection associated doxycycline with a small increased efficacy of about 3-7% compared with azithromycin [55] .
Ureaplasma respiratory tract colonisation in preterm infants has been associated with bronchopulmonary dysplasia [56] . Experimental evidence from animal models and adult humans suggest that azithromycin concentrations in AM in the lung may far exceed the Ureaplasma isolate minimum inhibitory concentrations. Some pharmacokinetic studies carried out in preterm neonates showed that a dosage regimen of three intravenous doses of 10-20 mg/ kg/day of azithromycin may be safe and may effectively eradicate Ureaplasma from the respiratory tract in all culture-positive subjects [57] [58] [59] . However, it should not be overlooked that antibiotic resistance against tetracyclines and fluoroquinolones has recently emerged among clinical Ureaplasma isolates recovered from neonates [60, 61] . Although currently antibiotic resistance among Ureaplasma isolates remains low, continued surveillance is essential to understand the future trend and to determine whether this might affect therapeutic effectiveness [61] .
Chronic Staphylococcal Infections
Staphylococcus aureus is a typical extracellular pathogen, which under some circumstances may behave as an intracellular opportunist [3] . The so-called SCVs are adapted phenotypes for the intracellular persistence of S. aureus [62] . Staphylococcus aureus SCVs showed an overexpression of adhesins, and this adaptation was associated with both enhanced biofilm formation and uptake by the host cells [63] . These variants are metabolically defective and replicate slowly [25] . They may produce fewer lytic enzymes, and this may allow survival within the host cells [25, 62, 63] .
This phenotype switching may represent an effective strategy for S. aureus in escaping host immune response and in causing chronic therapy-refractive infections [62, 64] . Notable examples of chronic antibiotic-refractory SCV staphylococcal infections may be endocarditis, prosthetic and device-related infections, and bone and joint infections.
Interestingly, it has been suggested that the persistence of S. aureus SCVs may be favoured by the relative inefficiency of antibiotics in clearing the microorganisms within host cells [65] . A recent retrospective study assessed comparatively the clinical outcomes of prosthetic joint infections caused by SCVs staphylococci (n = 38) vs. those caused by normal staphylococcal phenotypes (n = 75) [66] . Prosthetic joint infections caused by SCVs were associated with a longer duration of symptoms and with more prior treatment for infection.
Although no clinical trial to date examined therapeutic options against SCV infections, it is generally agreed that an effective regimen against SCVs should include rifampicin (against methicillin-resistant S. aureus) and/or a fluoroquinolone (against methicillin-sensitive S. aureus) [65, 67] . These agents either achieve high intracellular concentrations or have excellent in vitro activity against intracellular SCVs [65] . Conversely, beta-lactams and glycopeptides are considered less effective against SCVs, and this is consistent both with the reduced intracellular accumulation and with the lower in vitro activity exhibited by these antibacterial agents against intracellular SCVs [65] .
Rifampicin is considered the mainstay of therapy of staphylococcal prosthetic and/or bone and joint infections [67, 68] , and must always be administered with a second agent, given the high likelihood of generation of resistance when used alone [69] . A combination of rifampicin with the fluoroquinolone levofloxacin or moxifloxacin is currently recommended by several authors for the treatment of prosthetic and/or bone and joint infections caused by methicillin-susceptible S. aureus [70] [71] [72] . Conversely, when prosthetic and/or bone and joint infections are methicillin-resistant S. aureus related, rifampicin should be combined with the glycopeptides or with daptomycin [73] [74] [75] [76] . Aminoglycosides should not be used for the therapy of infections caused by S. aureus SCVs because it has been documented that under these circumstances there is a decreased bacterial uptake of these antimicrobial agents [77] .
Toxicological Implications: The Case of Aminoglycosides
Specific intracellular accumulation in some organs may justify the appearance of drug-related toxicity when using hydrophilic antimicrobials that are transported by tissuespecific carriers. This is the case with aminoglycosides. Aminoglycosides are typical hydrophilic agents. After systemic administration, distribution is limited to the extracellular milieu in most tissues. This is owing to the incapability of aminoglycosides to cross the plasmatic membrane of the eukaryotic cells by passive diffusion. Despite this and the low tissue distribution, it is well known that around 5-10% of patients receiving aminoglycosides may experience reversible drug-related nephrotoxicity [78] . This is owing to the fact that aminoglycosides may enter the renal tubular cell via the multi-ligand receptor megalin [4, 79] . It has been estimated that up to 15% of a filtered aminoglycoside load may undergo tubular reabsorption after glomerular filtration [80] , and that up to 5% of the administered dose may accumulate within renal tubular cells [81] . Unfortunately, excretion of aminoglycosides from this intracellular compartment occurs very slowly, and may take several days [82] . Although the exact mechanism of renal toxicity is still to be fully elucidated [4] , it should not be overlooked that the uptake of the aminoglycosides into the cells of the proximal tubule in the renal cortex is a saturable process [83] . This fact has important clinical implications.
It has been demonstrated that careful dosing strategies may reduce the incidence of nephrotoxicity in patients treated with aminoglycosides. A randomised prospective clinical trial was performed to determine the incidence of nephrotoxicity after administration of 7 mg/kg/day of tobramycin to critically ill patients in two different ways: pulse once-daily dose (ODD group) compared with twice multiple-daily dose (MDD group) [84] . Patients in the two groups had similar values of creatinine clearance at baseline (p = 0.36), but at the end of therapy patients in the ODD group (n = 25) had higher measured creatinine clearance compared with those in the MDD group (70 ± 18.6 vs. 64.8 ± 17.5 mL/min, p = 0.047). Although an increase of the urinary surrogate markers of nephrotoxicity (alanine aminopeptidase; N-acetyl-beta-Dglucosaminidase) occurred in both groups, these were significantly higher in the MDD group than in the ODD group (alanine aminopeptidase, 8.7 ± 2.9 vs. 5.2 ± 2.1 units/24 h, p \ 0.01; N-acetyl-beta-D-glucosaminidase, 14.7 ± 4.9 vs. 6.8 ± 3.1, p \ 0.01) [84] . Consistently, it was concluded that ODD of tobramycin is less nephrotoxic than MDD, in line with the saturable uptake of the aminoglycosides in the kidney.
The less nephrotoxic effect of ODD compared with MDD of tobramycin was subsequently confirmed also in a randomised controlled trial conducted among patients with cystic fibrosis [85] , and in a subsequent meta-analysis in children [86] . It is worth noting that ODD is currently the recommended mode of administration of aminoglycosides in all of the indications, including those of gentamicin for the treatment of endocarditis [87, 88] . A recent retrospective case series of gentamicin 3-mg/kg once-daily dosing in the treatment of enterococcal endocarditis suggested that this approach may be a safe option [89] .
Other Implications in Clinical Practice:
Different Implications for Loading with Hydrophilic and Lipophilic Antimicrobials in the Treatment of Sepsis
The capability or incapability of antimicrobials of penetrating and accumulating within cells according to the intrinsic physicochemical properties may significantly affect the pharmacokinetic behaviour of antibacterials in the early phase of sepsis [6] . Sepsis is a life-threatening disease with organ dysfunctions, which is caused by a dysregulated host response to infections [90] . Starting appropriate antimicrobial treatment with broad-spectrum antimicrobials at the right dosage, ideally within 1 h from the diagnosis of sepsis, is presently considered absolutely mandatory to reduce the risk of mortality of patients with sepsis in the early phase [90] .
In this regard, it should not be overlooked that starting antimicrobial therapy by administering a standard loading dose (LD) may cause subtherapeutic concentrations in patients with sepsis when using a hydrophilic antimicrobial [1, 91] . This is because of the significant increase that the V d of hydrophilic antimicrobials may have in patients with sepsis. Volume of distribution expansion is the consequence of fluid extravasation in tissues, which is caused by the sharp spillage of serum albumin in relation to the sudden capillary leakage [91, 92] .
Several clinical studies showed the necessity of administering higher LDs of hydrophilic antimicrobials for rapidly achieving therapeutically effective concentrations in patients with sepsis. This has been demonstrated especially for the aminoglycosides [93] [94] [95] [96] [97] and for the glycopeptides [98, 99] . As a general rule, it has been suggested that, to rapidly achieve therapeutically effective concentrations, the LD of hydrophilic antimicrobials in patients with sepsis should be at least 1.5-fold higher than the standard one that is administered to clinically stable patients [6] .
Conversely, there is no need to increase the LD of lipophilic antimicrobials in patients with sepsis [6] . These agents may accumulate intracellularly, and consistently their V d is only minimally affected in patients with sepsis. This is owing to the fact that for these agents, cells may represent a reservoir from which the drug may retrodiffuse in the extracellular milieu and may equilibrate the concentrations in the interstitium [6, 91, 92] . Accordingly, no sub-therapeutic concentrations are expected when standard LDs of lipophilic agents are administered to patients with sepsis. This was well demonstrated with the oxazolidinone linezolid, for which after a single 600-mg intravenous dose, plasma drug exposure in patients with severe sepsis and/or with septic shock did not significantly differ from that observed in healthy volunteers [100] .
Conclusions
Intracellular pharmacokinetics of antimicrobials may have several clinical implications. Therapeutic efficacy against intracellular pathogens has been correlated mainly with the intracellular concentrations achieved by the different classes of antimicrobials into surrogate markers, such as AM in bronchoalveolar lavage and/or WBC. This is relevant especially for macrolides, tetracyclines, fluoroquinolones and rifampicin in the treatment of L. pneumophila pneumonia, M. pneumoniae pneumonia, nongonococcal urethritis and chronic staphylococcal infections caused by SCVs. Additionally, intracellular accumulation of antibacterials was correlated with the potential of causing organ-specific toxicity, as in the case of aminoglycosides with regard to the risk of nephrotoxicity. Finally, clinicians should bear in mind that intracellular accumulation may also represent a drug reservoir for lipophilic antimicrobials, whose pharmacokinetics in the early phase of sepsis is only minimally affected by the severity of illness, differently from what may occur with hydrophilic antimicrobials.
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